全文获取类型
收费全文 | 947篇 |
免费 | 49篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 14篇 |
妇产科学 | 22篇 |
基础医学 | 125篇 |
口腔科学 | 5篇 |
临床医学 | 75篇 |
内科学 | 80篇 |
皮肤病学 | 24篇 |
神经病学 | 73篇 |
特种医学 | 12篇 |
外科学 | 283篇 |
综合类 | 5篇 |
预防医学 | 54篇 |
眼科学 | 13篇 |
药学 | 98篇 |
肿瘤学 | 96篇 |
出版年
2023年 | 4篇 |
2022年 | 6篇 |
2021年 | 9篇 |
2020年 | 12篇 |
2019年 | 18篇 |
2018年 | 15篇 |
2017年 | 9篇 |
2016年 | 14篇 |
2015年 | 19篇 |
2014年 | 14篇 |
2013年 | 24篇 |
2012年 | 44篇 |
2011年 | 58篇 |
2010年 | 23篇 |
2009年 | 26篇 |
2008年 | 46篇 |
2007年 | 43篇 |
2006年 | 39篇 |
2005年 | 54篇 |
2004年 | 39篇 |
2003年 | 38篇 |
2002年 | 39篇 |
2001年 | 20篇 |
2000年 | 37篇 |
1999年 | 28篇 |
1998年 | 18篇 |
1997年 | 14篇 |
1996年 | 27篇 |
1995年 | 15篇 |
1994年 | 11篇 |
1993年 | 10篇 |
1992年 | 30篇 |
1991年 | 38篇 |
1990年 | 20篇 |
1989年 | 21篇 |
1988年 | 23篇 |
1987年 | 19篇 |
1986年 | 16篇 |
1985年 | 16篇 |
1984年 | 10篇 |
1983年 | 7篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 6篇 |
1978年 | 7篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
排序方式: 共有998条查询结果,搜索用时 15 毫秒
21.
K. Ezz El Din W.F.R.M. Koch M.J. A.M. de Wildt L.A.L.M. Kiemeney F.M.J. Debruyne J.J.M.C.H. de la Rosette 《The Journal of urology》1996,155(6):1959-1964
Purpose
The reliability of the International Prostate Symptom Score (I-PSS) was tested in patients with lower urinary tract symptoms and/or benign prostatic hyperplasia.Materials and Methods
A total of 71 consecutive men with benign prostatic hyperplasia and/or lower urinary tract symptoms was asked to complete the I-PSS at baseline and 8 weeks later. At the second visit the physician also completed the I-PSS according to the complaints of the patient. Variability between both scores was evaluated by calculation of duplo errors and results were compared to the clinical data.Results
A considerable variability existed between the I-PSS results obtained at baseline and 8 weeks. The duplo error was 4.3. In a regression analysis of I-PSS, including all clinical parameters, only free flow had some predictive value for I-PSS outcomes.Conclusions
It is important to consider the variability of the I-PSS score when making decisions concerning treatment. 相似文献22.
Wim P.J. Witjes Peter F.W.M. Rosier Michel J. A.M. de Wildt Matheus P. van Iersel Frans M.J. Debruyne Jean J.M.C.H. de la Rosette 《The Journal of urology》1996,155(4):1317-1323
Purpose
We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH).Materials and Methods
A total of 45 patients who participated in a multicenter trial was evaluated with urodynamic pressure-flow studies before and after 26 weeks of treatment.Results
Maximum flow rate and symptom score improved significantly in 22 patients with and 11 without bladder outlet obstruction who completed 26 weeks of treatment. In patients with bladder outlet obstruction the condition was significantly reduced and in patients without obstruction, significant urodynamic changes could not be detected.Conclusions
Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction. 相似文献23.
D Bigot-Lasserre F Chuzel E L M Debruyne R Bars N G Carmichael 《Food and chemical toxicology》2003,41(1):99-106
The heterozygous p53 knockout mouse model was used to assess whether vascular tumors noted in a 2-year carcinogenicity study in CD-1 mice with carbaryl were induced through a genotoxic mechanism. This knockout mouse model was selected for carbaryl because of the high sensitivity of this model to genotoxic events and its low spontaneous incidence of tumors until 9-12 months of age. Carbaryl was administered continuously via the diet to groups of 20 male heterozygous p53 knockout mice at concentrations of 0, 10, 30, 100, 300, 1000 and 4000 ppm for 180 days. Histopathological examinations revealed no evidence of carbaryl-induced neoplasms of any type. In particular, no neoplastic or preneoplastic changes were noted in the vascular tissue of any of the organs examined. Only neoplasms, recognized as those that occur spontaneously in untreated mice of this strain, were sporadically observed in a few animals from the intermediate dose groups with no evidence of a dose- or treatment-related effect. Therefore, under the conditions of this study, the no-observed-effect level (NOEL) of carbaryl for neoplastic changes in male mice was 4000 ppm (around 716 mg/kg body weight/day). We conclude: (1) carbaryl does not appear to be a genotoxic carcinogen at least in male mice; (2) if the vascular tumors observed in the CD-1 mice are treatment-related, they could have been induced by a non-genotoxic mechanism; (3) the response in transgenic animals may provide useful complementary results to better assess carbaryl's potential genotoxic hazard to humans. 相似文献
24.
25.
26.
27.
28.
John T. Heap Jan Theys Muhammad Ehsaan Aleksandra M Kubiak Ludwig Dubois Kim Paesmans Lieve Van Mellaert Richard Knox Sarah A. Kuehne Phillipe Lambin Nigel P. Minton 《Oncotarget》2014,5(7):1761-1769
Spores of some species of the strictly anaerobic bacteria Clostridium naturally target and partially lyse the hypoxic cores of tumors, which tend to be refractory to conventional therapies. The anti-tumor effect can be augmented by engineering strains to convert a non-toxic prodrug into a cytotoxic drug specifically at the tumor site by expressing a prodrug-converting enzyme (PCE). Safe doses of the favored prodrug CB1954 lead to peak concentrations of 6.3 μM in patient sera, but at these concentration(s) known nitroreductase (NTR) PCEs for this prodrug show low activity. Furthermore, efficacious and safe Clostridium strains that stably express a PCE have not been reported. Here we identify a novel nitroreductase from Neisseria meningitidis, NmeNTR, which is able to activate CB1954 at clinically-achievable serum concentrations. An NmeNTR expression cassette, which does not contain an antibiotic resistance marker, was stably localized to the chromosome of Clostridium sporogenes using a new integration method, and the strain was disabled for safety and containment by making it a uracil auxotroph. The efficacy of Clostridium-Directed Enzyme Prodrug Therapy (CDEPT) using this system was demonstrated in a mouse xenograft model of human colon carcinoma. Substantial tumor suppression was achieved, and several animals were cured. These encouraging data suggest that the novel enzyme and strain engineering approach represent a promising platform for the clinical development of CDEPT. 相似文献
29.
30.
Li X Tjwa M Van Hove I Enholm B Neven E Paavonen K Jeltsch M Juan TD Sievers RE Chorianopoulos E Wada H Vanwildemeersch M Noel A Foidart JM Springer ML von Degenfeld G Dewerchin M Blau HM Alitalo K Eriksson U Carmeliet P Moons L 《Arteriosclerosis, thrombosis, and vascular biology》2008,28(9):1614-1620